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a b s t r a c t
The acute radiation syndrome (ARS) occurs after whole-body or signiﬁcant partial-body
irradiation (typically at a dose of >1Gy). ARS can involve the hematopoietic, cutaneous,
gastrointestinal and the neurovascular organ systems either individually or in combination.
There is a correlation between the severity of clinical signs and symptoms of ARS and
radiation dose. Radiation induced multi-organ failure (MOF) describes the progressive dys-
function of two or more organ systems over time. Radiation combined injury (RCI) is deﬁned
as radiation injury combined with blunt or penetrating trauma, burns, blast, or infection.
The classic syndromes are: hematopoietic (doses >2–3Gy), gastrointestinal (doses 5–12Gy)
and cerebrovascular syndrome (doses 10–20Gy). There is no possibility to survive after doses
>10–12Gy.
The Phases of ARS are—prodromal: 0–2 days from exposure, latent: 2–20 days, and manifest
illness: 21–60 days from exposure.
Granulocyte-colony stimulating factor (G-CSF) at a dose of 5g/kg body weight per day sub-
cutaneously has been recommended as treatment of neutropenia, and antibiotics, antiviral
and antifungal agents for prevention or treatment of infections.
If taken within the ﬁrst hours of contamination, stable iodine in the form of nonradioac-
tive potassium iodide (KI) saturates iodine binding sites within the thyroid and inhibits
incorporation of radioiodines into the gland.
Finally, if severe aplasia persists under cytokines for more than 14 days, the possibility of a
hematopoietic stem cell (HSC) transplantation should be evaluated.This review will focus on the clinical aspects of the ARS, using the European triage system
(METREPOL) to evaluate the severity of radiation injury, and scoring groups of patients for
the general and speciﬁc management of the syndrome.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.1. IntroductionThe acute radiation syndrome (ARS) is a broad term used to
describe a range of signs and symptoms that reﬂect severe
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1507-1367/$ – see front matter © 2011 Greater Poland Cancer Centre, Poland
doi:10.1016/j.rpor.2011.05.001damage to speciﬁc organ systems and that can lead to death
within hours or up to several months after exposure.1 Thee la Princesa, C/Diego de León 62, CP 2006 Madrid, Spain.
ARS occurs after whole-body or signiﬁcant partial-body irradi-
ation of greater than 1Gy, over a short time period (high dose
rate).
. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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Radiation injury can occur from external irradiation;
xternal contamination with radioactive materials; and inter-
al contamination by inhalation, ingestion, or transdermal
bsorptionwith incorporationof radiologicmaterials into cells
nd tissues. The reaction of an individual to an exposure
epends on a number of independent variables, including the
ose, the dose rate, the nature and energy of the radiation, the
ype and volume of tissue irradiated, age and state of health,
nd the quality of medical care available.2
Three forms of energy are released from a nuclear detona-
ion: heat, accounting for approximately 35% of total energy;
hockor bombblast, accounting for approximately 50%of total
nergy; radiation, accounting for the remaining 15% of total
nergy.
Our aim is to review the clinical aspects of the ARS, how
o assess the severity of radiation injury, and evaluate the
ifferent treatments for the syndrome.
. Biology and clinical features of radiation
njury
everal factors determine the lethality of ionizing radiation.
hese include:
(a) Dose rate: Doses received over a shorter period of time
cause more damage.
(b) Distance from the source: For point sources of radiation, the
dose rate decreases as the square of the distance from the
source (inverse square law).
(c) Shielding: Can reduce exposure, depending upon the type
of radiation and the material used.3
d) Available medical therapy: Is critical for those exposed to
moderately high doses of radiation.
The lethal dose at 60 days (The LD50/60 is deﬁned as the
ose necessary to cause death in 50% of an irradiated pop-
lation in 60 days) for humans has been estimated to be
pproximately 3.5–4.0Gy in persons managed without sup-
ortive care, 4.5–7Gy when antibiotics and treatment support
re provided, and potentially as high as 7–9Gy in patients
ith rapid access to intensive care units, reverse isolation,
ndhematopoietic cell transplantation.4,5 There is virtually no
hance of survival following a total body exposure in excess
f 10–12Gy.
Ionizing radiation may interact directly with intracellular
argets or may interact with other molecules (e.g., water) to
roduce free radicals that, in turn, reach and damage a tar-
et (e.g., DNA, mRNA, proteins, plasma membrane). The most
ritically affected tissues in adults include the following: sper-
atocytes in the testis, hematopoietic precursor cells in the
one marrow and crypt cells in the intestines.
Dose-dependent effects on various organs have also been
dentiﬁed. They are of two types, deterministic and stochastic:(a) A deterministic effect is one in which the severity is deter-
minedby thedose (e.g., depressionof blood counts). Adose
threshold is characteristic of this effect. As an example,
the threshold absorbed dose for a “deterministic effect”therapy 1 6 ( 2 0 1 1 ) 138–146 139
on bone marrow (0.5Gy) is lower than that for all other
organs, except for the testis (0.15Gy).
(b) A stochastic effect represents an outcome for which the
probability of occurrence (rather than severity) is deter-
mined by the dose. An example is radiation-induced
carcinogenesis, which occurs after a prolonged and vari-
able delay (latency) after exposure. These effects do not
have an apparent threshold dose.
3. Assessment of radiation dose
a) Physical measurement: Physical dosimetry can provide an
estimate of individual dose, using a whole-body radiation
dosimeter. Few whole-body dosimeters are available for
rapid assessment of dose. Reconstruction of dose can be
made with considerable sensitivity, using environmental
measurements combined with time-integrated activity.6,7
However, this is a time-consuming process that is imprac-
tical in an emergency situation, particularly when there
are many potentially exposed persons.
Estimation of the internal dose from the deposition of
radioactive materials, such as alpha emitters (e.g., pluto-
nium, americium, californium) and beta-gamma emitters
(e.g., cesium, cobalt and iodine) into the lungs, gastroin-
testinal tract, and other tissues, requires detection with
special instrumentation (such as ion chambers and spec-
troscopes). In this case, measurements are made on body
ﬂuids (blood, urine and saliva), nasal swipes, fecal sam-
ples, and/or expired air.8
b) Biological and clinical markers: Currently, the threemost clin-
ically useful markers are the time to onset of emesis,
lymphocyte depletion kinetics, and chromosomal aber-
rations. Monitoring the decrease in absolute lymphocyte
count has been found to be the most practical method to
assess the radiation dose within hours or days following a
radiation exposure.9 The time to emesis and lymphocyte
depletion kinetics are dose-related and are amenable to
quantitative analysis with respect to dose.10 The rate of
decline and nadir of the absolute lymphocyte count over
the initial 12h to 7 days after exposure is a function of
cumulative dose. Lymphocyte depletion kinetics predict
dose for a photon-equivalent dose range between 1 and
10Gywith an exposure resolution of approximately 2Gy.2,9
The three elements (i.e., time to onset of vomiting, lym-
phocyte depletion kinetics, and chromosome aberrations)
should be sought for the most accurate assignment of
prognosis and selection of therapy. As a practical matter,
however, only the time of onset of vomiting and lym-
phocyte depletion may be available within the ﬁrst 24h
following exposure.
(c) Chromosomal changes: The frequency of chromosomal
aberrations (e.g., dicentrics, chromosomal rings) in lym-
phocytes are correlated to radiation dose.11 A peripheral
blood sample should be obtained at 24h after exposure
(or later) in accordance with the policies of a qualiﬁed
radiation cytogenetic biodosimetry laboratory. Because of
incubation times, results will not be available for 48–72h
after the sample has been submitted for analysis.12
d rad
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Initial laboratory testings according to European consen-
sus, within the ﬁrst 48h are13:
(a) Repeated blood cell counts (lymphocites, granulocytes and
platelets) if possible every 4–8h for the ﬁrst 24h, then every
12–24h (+reticulocytes).
(b) Chromosome aberration analysis on blood lymphocytes
(biodosimetry).
(c) Red cell group typing.
d) Store serum and cells for DNA for future analyses includ-
ing HLA typing upon request from clinical teams.
(e) Standard biochemical tests (+amylasemia).
(f) If there is suspicion of a neutron exposure, a blood sam-
ple of 20ml should be taken to measure the content of
radioactive sodium (24Na).
(g) Urine and feces if radionuclide contamination is sus-
pected.
The timeof CBC collectionmust be carefully noted, because
of important time-related changes in the lymphocyte count.
Additional monitoring should be based on the whole-body
dose, as the onset of neutropenia and its severity are dose
dependent. Patients with low exposures may need a weekly
or twice-weekly CBC for 4–6 weeks to document their WBC
nadir and subsequent recovery.
The various cytogenetics methods, including dicentric
assay (DA) and ﬂuorescence in situ hybridization (FISH) assay,
offer high-accuracy exposure dose determination, yet require
a long sample-processing time.
4. Scoring the severity of radiation
exposure
The European protocol METREPOL (Medical Treatment Proto-
cols for radiation accident victims; this protocol forms the
basis of a computarized guidance system) agreed that the
ﬁrst 48h after a radiological accident involving masses of
people are crucial. In that time period, the accident victims
should be processed by an emergency triage system where
the patients are scored on the basis of both clinical and bio-
logical criteria, including the delay before symptoms appear,
the delay before cutaneous erythema is observed, the sever-
ity of asthenia, the intensity of nausea, the frequency of
vomiting per 24h, the severity and frequency of diarrhea
or number of stools per 24h, the presence of abdominal
pain, the intensity of headaches, temperature, blood pressure,
and the occurrence of temporary loss of consciusness13,14
(Table 1).
Patients with a score of 1 can be followed up on an out-
patient basis or be treated by the equivalent of a day care
hospital. Patientswith a score of 2 are those patientswhoneed
maximum medical attention if they are to survive. Patients
with a score of 3 are those patients who are predicted to
develop multi-organ failure (MOF) and unfortunately have
almost no hope of recovering. Radiation induced multi-organ
failure (MOF) describes the progressive dysfunction of two or
more organ systems over time.
A primary objective in the ﬁrst 48h is to identify bystanders
whowerenot irradiated (score 0). Thiswill help to prevent hos-iotherapy 1 6 ( 2 0 1 1 ) 138–146
pitals from exceeding their saturation capacity. The patients
who are hospitalized are only those who have a score exceed-
ing 1. In the case of accidental contamination, only those
patientswhohave been appropriately decontaminated should
be admitted.
After the initial 48h, scoring of the patient is re-evaluated
on the basis of METREPOL.15 Patients who receive a score of 2
or 3 then receive the recommended treatment, regardless of
whether they have any hope of recovering. It is unfortunately
not possible to know during the ﬁrst 48h the individual phys-
ical and biological dosimetry: these key pieces of information
only become accessible after 48h, at which point they become
the basis of further medical decision-making. It should be
noted that which body portion of an individual is exposed is
more important than the overall dose of exposure.
Some authors propose screening methods based on high-
accuracy biodosimetry such as in vivo electron paramagnetic
resonance (EPR) dosimetry of tooth and nail tissue for triage
during a catastrophic nuclear event.16
5. Contamination
Once the patient is medically stabilized, alpha and Geiger
counters must be used to evaluate radioactivity and docu-
mented on an anatomic chart. To assess the possibility of
internal contamination, separate saline or water moistened
swabs should be used to wipe the skin, nares, ears, mouth,
and wounds. These swabs should be assessed for radioactivity
with a Geiger counter or alpha-radiation detection device.17
Decontamination should begin with debridement of open
wounds to remove as much debris as possible. Wounds should
be copiously irrigated with normal saline until they are free
of radioactivity, and then covered with a waterproof dressing.
Contaminated burns should be treated as any other thermal
or chemical burn.18
Patients with internal contamination usually pose no haz-
ard to caregivers or to the medical facility, although their
fecal and urinary excretion products should be measured for
radioactivity and disposed of in marked, sealed containers.19
Chelating agents such as dyethilene-triamine-pentacetic
acid (DTPA) as the zinc or calcium salts (Zn and Ca-DTPA) can
expedite the removal of radioisotopes such as plutonium-239
or yttrium-90. Sodiumbicarbonate is used to treat renal chem-
ical toxicity of uranium and reduce the risk of acute tubular
necrosis (which is generally a far greater hazard than its
radiologic toxicity). Oral administration of insoluble Prusian
blue is the countermeasure of choice for Cesium-137 (found
in high concentrations for miles around Chernobyl following
the accident) rubidium-82, or thallium-201. Oral calcium or
aluminium phosphate solutions can block the absorption of
strontium through competitive inhibition.
Radioiodines are known from Chernobyl data to cause thy-
roid injury and tobe carcinogenic, especially to the fetus and to
children under 18 years of age. If takenwithin 4–6h of contam-
ination, stable iodine in the form of nonradioactive potassium
iodide (KI) saturates iodine binding sites within the thyroid
and inhibits incorporation of radioiodines into the gland20;
131I and 137Cs are the most signiﬁcant for dose received by
the exposed population in Chernobyl.
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Table 1 – Primary scoring (ﬁrst 48h).
Score 1 Score 2 Score 3
Average delay before
symptoms appear
Less than 12h Less than 5h Less than 30min
Cutaneous erythema 0 +/− +++; before 3h
Asthenia + ++ +++
Nausea + +++ ++++
Vomiting per 24h Maximum 1 1–10 Above 10; intractable
Diarrhea/number of stools per
24h
Maximum 2–3; bulky 2–9; soft Above 10; watery
Abdominal pain Minimal Intense Excruciating
Headache 0 ++ Excruciating; signs of cranial
HT
Temperature Below 38 ◦C 38–40 ◦C Above 40 ◦C
Blood pressure Normal Normal; possible temporary
decrease
Systolic below 80
Temporary loss of
consciousness
0 0 +/coma
Depletion of blood lymphocytes
At 24h Above 1500/mcl Below 1500/mcl Below 500/mcl
At 48h Above 1500/mcl Below 1500/mcl Below 100/mcl
Outpatient monitoring Hospitalization for curative Hospitalization multi-organ
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s. Phases of acute radiation injury
he most rapidly dividing cells are the most sensitive to the
cute effects of radiation. Symptoms arising from such expo-
ures are referred to as acute radiation syndrome (ARS).
Classically, the threshold dose for ARS is a whole-body or
igniﬁcant partial-body irradiation of greater than 1Gy deliv-
red at a relatively high dose rate. The signs and symptoms of
RS are related to the whole-body absorbed dose of radiation.
oses less than 0.5Gy are not expected to cause acute symp-
oms, whereas doses of 4.5Gy are lethal to 50% of exposed
ersons. The ARS progresses through three phases21:
) Prodromal phase: 0–2 days after exposure.
) Latent phase: 2–20 days after exposure.
) Manifest illness: 21–60 days after exposure.
The onset, duration, and dominant manifestation of the
yndrome depend upon the dosage of radiation received.
cute changes, which are seen within the ﬁrst 2 months
ollowing exposure, include signs and symptoms resulting
ainly from damage to the skin, CNS, lung, GI tract, and
ematopoietic tissues. Classic clinical syndromes associ-
ted with ARS include the hematopoietic, gastrointestinal,
nd cerebrovascular syndromes, although there is signiﬁcant
verlap22 (Table 2). The cutaneous syndrome (CS) is especially
ommon and important in patients with ARS consequent to a
on-uniform exposure. The CS may include changes ranging
rom epilation to radionecrosis.
.1. Prodromal phasearly symptoms resulting from an acute total-body exposure
onstitute the prodromal radiation syndrome. These early
ymptoms include anorexia, apathy, nausea, vomiting, diar-treatment failure (MOF) predicted
rhea, fever, tachycardia and headache and are dependent on
the magnitude of radiation dose and the presence of addi-
tional injury. The prodromal syndrome is generally mild or
absent at total body doses of 1Gy or less. Onset of symptoms
within the ﬁrs 2h usually indicates signiﬁcant and potentially
lethal exposures exceeding 2Gy. At these doses, the gastroin-
testinal syndrome adds to the symptomatology. At high doses
(e.g., 10 to >20Gy), prodromal symptoms occur in virtually
all patient within minutes of exposure.23,24 The cerebrovas-
cular syndrome appears and death often occurs within few
days to weeks after such exposures. Those patients who do
not present with the cerebrovascular syndrome but develop
the gastrointestinal syndrome may survive with appropriate
medical support. However, all will also develop the hemato-
logic syndrome if they survive long enough. The cutaneous
syndrome may develop in any of the above scenarios and will
complicate management.
6.2. Cerebrovascular syndrome
In general, cerebrovascular symptoms only occur at whole-
body doses in excess of 10Gy. Also called neurovascular
syndrome or CNS syndrome, results from localized changes in
the central nervous system. These include impaired capillary
circulation with damage to the blood–brain barrier, inter-
stitial edema, acute inﬂammation, petequial hemorraghes,
inﬂammation of the meninges, and hypertrophy of perivas-
cular astrocytes.15 Presence of swelling and edema may be
documented by CT scans and MRI of the head. With doses
in the range of 10–20Gy, individuals present with persistent
and severe nausea and vomiting, accompanied by headache,
neurologic deﬁcits, and abnormal cognition. Signs and symp-
toms include disorientation, confusion, loss of balance,
and seizures. Physical examination may show papilledema,
ataxia, and reduced of absent deep tendon and corneal
reﬂexes.
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Table 2 – Radiation effects.
Dose (Gy) 20 and above Neurovascular syndrome onset (>10Gy) Multiple organ failure probable death
(8–10Gy) Consider stem cell transplant
t
drom6Gy GI syndrome onse
1Gy Hematopoietic syn
6.3. Gastrointestinal syndrome
The gastrointestinal syndrome typically develops within ﬁve
days of the initial exposure. At doses<1.5Gy, only the pro-
dromal phase of nausea, vomiting, and gastric atony are
observed.25 More severe symptoms develop at doses between
5 and 12Gy,26 secondary to loss of intestinal crypt cells
and breakdown of the mucosal barrier. These changes result
in crampy abdominal pain, diarrhea, nausea and vomiting,
gastrointestinal bleeding with resultant anemia, and abnor-
malities of ﬂuid and electrolyte balance. This early phase
is often followed by a latent phase lasting 5–7 days, during
which symptoms abate. Vomiting and severe diarrhea accom-
panied by high fever make up the manifest illness. Systemic
effects at this timemay includemalnutrition frommalabsorp-
tion. Impaired barrier function of the gastrointestinal tract
results in the passage of bacteria and their toxins through the
intestinal wall into the bloodstream, predisposing to infection
and sepsis, which may further be compromised by immuno-
suppression and cytopenia secondary to development of the
hematopoietic syndrome. Other severe complications include
ulceration and necrosis of the bowel wall, leading to stenosis,
ileus, and perforation.
6.4. Hematopoietic syndrome
The hematopoietic syndrome resulting from radiation injury
occurs at whole-body doses of 2–3Gy or higher.27 In addition
to inducing apoptosis, whose effect is not seen before the
ﬁrst cell cycle following radiation exposure, radiation alters
recirculation properties of lymphocytes.28 Neutropenia and
thrombocytopenia reach a nadir at 2–4 weeks and may persist
for months. Anemia inevitably ensues, due to the combined
effects of gastrointestinal blood loss from the gastrointestinal
syndrome, hemorraghe into organs and tissues secondary to
thrombocytopenia, and, ultimately, bone marrow aplasia.
In the ensuing weeks to months after exposure, hypoplasia
or aplasia of the bone marrow occurs, resulting in pancytope-
nia, predisposition to infection, bleeding, and or poor wound
healing, all of which may contribute to death in the absence of
appropriate supportive care. Inhomogeneity of dose, afforded
by partial shielding or a more ventral exposure may imply
bonemarrow sparing. Such sparings contribute to the reestab-
lishment of hematopoiesis.
Selective radioresistant subpopulations of stem cells
and/or accessory cells exist. Subpopulations of stem cells or
accessory cells are selectively more radioresistant, presum-
ably because of their largely noncycling (Go) state.29,30 These
may play an important role in recovery of hematopoiesis after
exposure to doses as high as 6Gy, albeit with a reduced capac-
ity for self-renewal.31
Lymphopenia is common and occurs before depression
of the other cellular elements, and may develop within the(6–7Gy) LD50/60 with supportive care
(3–5Gy) LD50/60 without treatment
e onset (0–2Gy) ∼100% survival without treatment
ﬁrst 6–24h after exposure to a moderate to high dose.9 A
50% decline in the absolute lymphocyte count within the
ﬁrst 24h after exposure, followed by a further more severe
decline within 48h, characterizes a potentially fatal exposure
in the range of 5–10Gy. An absolute lymphocyte count that
remains within 50% of normal during the ﬁrst week following
exposure suggests an exposure of <1Gy and a survival proba-
bility in excess of 90%. However, since lymphopenia can also
result from stresses accompanying burns and trauma,32,33 it
is always important to examine more than one biodosimetry
element (e.g., prodromal symptoms, lymphocyte dicentrics)
whenever possible.
The initial neutrophil nadir occurs at approximately 1week
following exposure, afterwhich theremaybe anabortive, tran-
sient rise in the absolute neutrophil count following exposure
to doses less than 5Gy. Presence of this abortive rise may
indicate a survivable exposure.34 Amore profound and longer-
lasting neutrophil nadir occurs at 2–4 weeks post-exposure,
and may last for many weeks.
6.5. Cutaneous syndrome
The cutaneous syndrome may develop early following expo-
sure (e.g., 1–2 days). However, it may take years before
becoming fully manifest. Early lesions include erythema,
edema, and dry descamation of the skin. More advanced
lesions include bullae, moist descamation, ulceration, and
onycholisis.35,36 Ulceration may be limited to the epidermis or
may involve deeper structures, such as dermis, subcutaneous
tissue, and even muscle and/or bone.
7. Treatment of radiation injury
Patients with acute, high dose, whole body irradiation will fall
into one of three categories: those who recover with min-
imal intervention; those who require aggressive supportive
care, up to and including bone marrow stem cell transplants;
those who, due to the dose they received, concomitant physi-
cal trauma, or inadequate clinical resources, will be triaged to
receive palliative care. Treatment of the ARS is not indicated
when exposure dose is very low (<1Gy) or very high (>10Gy).
Obtaining a history and physical examination, removal
of external contamination, dose estimation, supportive care
(including psychological support of the patient and family),
symptomatic treatment, and replacement of ﬂuids and elec-
trolytes should be the earliest goals ofmedicalmanagement.37
Reverse isolation is needed for patientswithwhole body doses
greater than 2–3Gy and antacids and H2 blockers should be
avoided to maintain gastric acidity, using sucralfate to prevent
stress ulcers.22
Beyond the ﬁrst 48h, a second patient scoring is done
by organs (neurovascular, hematopoiesis, cutaneous and
reports of practical oncology and radio
Table 3 – Initial therapeutic management.
Score 1: Monitoring no cytokine
Outpatient clinical monitoring.
Blood count: every day for 6 days, then once a week for 2
months.
Score 2: Cytokines (curative)
G-CSF/KGF should be used as early as possible for 14–21 days.
EPO and stem cell factor questionable.
Symptomatic treatment for gastrointestinal damage.
If severe aplasia: protected environment.
Accidental radiation exposure is generally heterogeneous; some
under-exposed/protected regions of bone marrow can give rise
to endogenous hematopoietic recovery.
Score 3: Cytokines (until reappraisal of score)
Palliative/symptomatic treatment.
Re-evaluation during the ﬁrst week based on laboratory or
clinical.
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(Symptoms revealing irreversible organ damage/disfunction.
ut) according to the METREPOL Document for therapeutic
anagement and multiple organ failure (MOF) prediction14
Table 3).
Surgical intervention, when required, should be carried out
ithin 36h, and not later than 48h after exposure.38 Addi-
ional surgery, if required, should not be performed until
t least 6 weeks post-exposure, in order to assure recovery
rom the period of cytopenia and immunosuppression, which
ould otherwise seriously add to the risk of developing surgi-
al complications (i.e., infection and poor wound healing).
Following a large release of radioactive iodine, which is
nlikely with a radiologic dispersal device but probable with
nuclear weapon or power plant incident, public health ofﬁ-
ialsmay recommendadministration of potassium iodide (KI),
specially to children and pregnant women (Table 4).39
The following dosages of selective 5-HT3 receptor antago-
ists are recommended for radiation-induced emesis22:
Ondansetron—Initial: 0.15mg/kg IV; a continuous IV dose
ption consists of 8mg followed by 1mg/h for the next 24h.
ral dose: 8mg/8h as needed.
Granisetron—Oral dosage form (tablets): Dose is usually
milligram (mg) initially and repeated in 12h after the ﬁrst
ose. Alternatively, 2mg may be taken as one dose. IV dose is
ased on body weight; it is typically 10g (mcg) per kilogram
kg) of body weight.Table 4 – Potassium iodide recommended doses.
Adults >40 years of age with thyroid exposure
≥5Gy
130mgday−1
Adults 18–40 years of age with thyroid exposure
≥0.1Gy
130mgday−1
Pregnant or lactating women with thyroid
exposure ≥0.05Gy
130mgday−1
Children and adolescents 3–18 years of age with
thyroid exposure ≥0.05Gy
65mgday−1
Infants 1 month to 3 years of age with thyroid
exposure ≥0.05Gy
32mgday−1
Neonates from birth to 1 month with thyroid
exposure ≥0.05Gy
16mgday−1therapy 1 6 ( 2 0 1 1 ) 138–146 143
7.1. Blood products
Severe degrees of anemia and thrombocytopenia do not typ-
ically occur before 2–4 weeks following exposure, during
which time a sufﬁcient number of additional blood donors
may be identiﬁed when there are large numbers of injured
patients.
Unless the victim is known to have received <1Gy irra-
diation, all cellular products should be irradiated (25Gy) to
prevent transfusion-associated graft-versus-host disease, and
leukoreduced (except granulocyte transfusions) to diminish
the risk of febrile non-hemolytic reactions, immunosuppres-
sive effects of blood transfusions, platelet alloimmunization
and cytomegalovirus infection.40 Transfusion of platelets
remains primary therapy to maintain adequate platelet
counts. Requirement for platelet support depends on patient’s
condition. In irradiated patients with or without other major
medical problems, platelets should be maintained at greater
than 20000/(L. If surgery is needed, platelet count should be
greater than 75000/(L.
Use of erythropoietin (Epo) anemia therapy after radiation
injury is not recommended even though probably safe as ane-
mia is not generally life-threatening in this situation.41 There
is general agreement that granulocyte colony-stimulating
factor (G-CSF) is an acceptable choice for treatment of indi-
viduals receiving a whole-body dose of 3Gy or more, or when
clinical signs and symptoms indicate a level 3 degree of
toxicity.
Individuals receiving a whole-body dose of 2Gy with
mechanical trauma and/or burns (i.e., combined injury)
are candidates for cytokine therapy, as are individuals at
extremes of age (i.e., children<12 years of age and the
elderly). Since studies in animals suggest that the risk for
developing the hematopoietic syndrome may be reduced
when cytokines are administered early after exposure (i.e.,
in the ﬁrst 24h when apoptosis occurs), it has been rec-
ommended that CSFs be initiated as soon as possible
after receipt of a survivable whole-body dose of radia-
tion. Granulocyte-colony stimulating factor (G-CSF) at a
dose of 5g/kg body weight per day subcutaneously has
been recommended as treatment in this setting. Other
cytokines (e.g., pegylated G-CSF, granulocyte-macrophage
colony-stimulating factor (GM-CSF) or KGF (keratinocite grow
factor) may be considered. Cytokine therapy should be con-
tinued for 2–3 weeks or until the absolute neutrophil count
is >1000/L. On the other hand, individuals with degree
four hematopoietic toxicity are unlikely to have respon-
sive hematopoietic stem-progenitor cells. These individuals
are candidates for stem-cell transplantation. In this case,
cytokines may be useful in conjunction with the infusion of
hematopoietic stem/progenitor cells. The following cytokines
are available for patients expected to experience severe
neutropenia27:
Filgrastim (G-CSF) 2.5–5g/kg/d subcutaneously or the equiv-
2alent (100–200g/(m d)).
Sargramostim (GM-CSF) 5–10g/kg/d subcutaneously or
(200–400g/(m2 d)).
Pegﬁlgrastim (pegG-CSF) 6mg once subcutaneously.
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Table 5 – Speciﬁc therapeutic management.
No treatment if dose <1Gy or >10Gy.
Decontamination and use of chelating agents: DTPA, Prusian blue
and calcium/aluminium phosphate.
Potassium iodide (KI): saturates iodine binding sites within the
thyroid and inhibits incorporation of radioiodines into the gland.
Surgery when necessary must be realized during the ﬁrst 36h.
Platelet transfusion if <20000/mcl (>75000/mcl if surgery needed).
Prophylaxis of neutropenia:
ﬂuoroquinolone+antiviral + antifungal.
Neutropenia and fever: broad spectrum prophylactic
antimicrobials.
(
(
would also destroy the infrastructure necessary to care for
these patients.
Table 6 – Hematopoietic stem cell (HSC) transplantation.
HSC transplantation is not an emergency
It is crucial to avoid GVDH in order not to compromise an
endogenous recovery.
If severe aplasia persists under cytokines for more than 14 days,
possibility of an hematopoietic stem cell (HSC) transplantation.
Criteria to transplant:
Severe marrow aplasia persisting 14–21 days
No residual hematopoiesis
No irreversible organ damage
Type of graft:
Bone marrow
Peripheral blood HSC
Cord blood
Donnor in the following order of priority:
Identical twin
Family member matched for a minimum of 7/8 HLA antigens
Unrelated donor matched for 9/10 antigens
Cord blood matched for at least 4/6 antigens144 reports of practical oncology an
7.2. Antibiotics
Susceptibility to local and systemic infection after radiation
arises as a result of breeches in cutaneous and mucosal
barriers or immune suppression and neutropenia prophy-
laxis should include a ﬂuoroquinolone (e.g., levoﬂoxacin),
an antiviral agent (acyclovir or one of its congeners), and
an antifungal agent (ﬂuconazol). For those who experience
fever and signiﬁcant neutropenia (i.e., absolute neutrophil
count < 500/L), broad spectrum prophylactic antimicrobials
should be employed, as the neutropenic duration is likely to
be prolonged. The ﬁrst approach is intravenous (IV) antibiotic
monotherapy with either imipenem/cilastatin, meropenem,
piperacilin/tazobactam, or an extended-spectrum antipseu-
domonal cephalosporin (cefepime or ceftazidime). The second
approach is IV antibiotic combination therapy: aminoglyco-
side or cyproﬂoxacine plus antipseudomonal penicillin or
aminoglycoside plus antipseudomonal cephalosporine. The
third approach is the addition of IV Vancomycin for spe-
ciﬁc indications either to IV monotherapy or to combination
therapy.42 These agents should be continued until the patient
fails treatment, experiences a neutropenic fever, or experi-
ences neutrophil recovery (ANC>500/L).
The incidence of reactivation of cytomegalovirus (CMV)
in those patients harbouring a latent CMV infection may be
increased. If resources permit, CMV serologic status should
be assessed. Patients with evidence of early viremia should
be treated pre-emptively, prior to the development of CMV
disease, with either ganciclovir or valganciclovir. For those
patients with a history of CMV reactivation and continued
T-cell immunodeﬁciency (i.e., CD4 count<50/L), more pro-
tracted monitoring should be considered, such as every other
week until 6 months post-exposure.
The opportunistic pathogen pneumocystis jirovecii (p.
carinii) has unique tropism for the lungs, with rare dissem-
ination. Patients with profound T-helper cell depletion (i.e.,
absolute CD4 count<200/L) are at risk for infection. Pro-
phylaxis is warranted, given its associated high mortality,
although no deﬁned guidelines for monitoring of the CD4
count in irradiation patients exist. Extrapolating from the HIV
and stem cell transplant experience, the absolute CD4 count
should be assessed at approximately day 30 post-exposure,
and the every 3–6 months until the absolute CD4 count is
>200/L. Initiation and maintenance of prophylaxis is recom-
mended if the absolute CD4 count is <200/L. In patients with
persistent myelosupression, trimethoprim-sulfamethoxazole
should be avoided as it may worsen existing cytopenias.43 Dis-
continuation of prophylaxis can be considered when the CD4
count is >200/L (Table 5).
7.3. Hematopoietic cell transplantation
In the course of treatment of a patient suffering from ARS, it
may become necessary to perform a detailed analysis of the
residual hematopoiesis in aneffort to predict fromhematopoi-
etic recovery. A bonemarrowaspirate, possibly complemented
by a bone marrow biopsy, avoiding the evident sites of radia-
tion exposure, may be useful during days 14–21.
The METREPOL conference experts agreed that hematopoi-
etic stem cell (HSC) transplantation should not be performedSerologic Citomegalovirus (CMV) status.
Pneumocystis Carinii prophylaxis if CD4<200/L.
on radiation accident victims who have the potential of
endogenous hematopoietic recovery. Thus, emergency HSC
transplantation is not a necessity in accidental whole body
irradiation. Although a sample for HLA typing should be
taken immediately and the search for potential donor ini-
tiated early, the transplant itself should not be carried out
before a minimum observational period of 14–21 days has
elapsed13,14 (Table 6). The use of hematopoietic cell transplan-
tation (HCT) in these patients is complicated by a variety of
factors:
a) Radiation exposure is often not homogeneous. Some parts
of marrow-containing structures might be minimally or
uniradiated because the patient was partially shielded by
a barrier.
b) Concomitant injuries such as burns or trauma can greatly
complicate the care of patients who also have radiation-
induced bone marrow failure.
(c) Explosion of a nuclear device leading to mass casualtiesSource of stem cells (minimum doses of infusion):
2×106 CD34/kg (peripheral blood)
2×108 nucleated cells/kg (bone marrow)
3×107 nucleated cells (cord blood))
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nly a fraction of patients might beneﬁt from HCT (i.e., doses
f 7–10Gy for those receiving allogenic HCT and 4–10Gy for
hose able to receive autologous or syngenic HCT).
. Late effects
eukemia was the ﬁrst malignancy to be linked to radiation
xposure among atomic bomb survivors and has the high-
st radiation-related relative risk of all cancers, particularly
fter exposure in childhood. Increased risk has been observed
n numerous epidemiological studies, with risks becoming
pparent relatively soon after exposure (2–5 years).44
The most signiﬁcant scientiﬁc lesson learned from Cher-
obyl accident is that exposure to internal radiation in
hildhood and adolescence causes an increase in papillary
hyroid cancer. Twenty-ﬁve years after the accident, thyroid
ancer risk in exposed young people continues to be signiﬁ-
antly elevated. Although the main health effect of radiation
rom the Chernobyl accident observed to date is the dramatic
ncrease in thyroid cancer among persons exposed at young
ges, increases in the incidence of other types of cancer, in
articular breast cancer, have also been reported, but have not
een conclusively linked to radiation from the accident.45
Recently, evidence has also emerged suggesting that mod-
rate doses of ionizing radiation can contribute to excess
ardiovascular disease risks.46
Radiation injury to the lung is an important, medically
ifﬁcult aspect of high-dose radiation incidents. These com-
lications may arise due to doses to the lungs in excess of
–10Gy. Radiation-associated tissue hypoxia often perpetu-
tes further lung injury. Depending on the dose/dose rate and
olume of lung irradiated, acute radiation pneumonitis may
evelop, characterized by dry cough and dyspnea. Fibrosis
f the lung, which causes further dyspnea, is a possible late
omplication.22
During the ﬁrst trimester period of organogenesis, the
mbryo is sensitive to growth-retarding effects because of
he criticality of cellular activities and the high proportion of
adiosensitive cells. For uterine doses>0.5Gy, growth retarda-
ion, gross congenital malformations, and microcephaly have
een the predominant effects. The highest risk of mental
etardation is irradiation of the fetus during the period of
ajor neuronal migration (8–15 weeks) and the incidence is
ose dependent. At 1Gy fetal dose, approximately 75% will
xperience mental retardation. Conversely, at 16–25 weeks
estation, the fetus shows no increase in mental retardation
t fetal doses<0.5Gy.22
. Conclusion
adiation oncologists, nuclear medicine specialists, hematol-
gists, and health physicists, because of their knowledge of
adiation and its biologic effects, will have to contact other
hysicians, staff and authorities, for training and evaluating
ocal infrastructures for the management of the acute radia-
ion syndrome.
Health personnel must be prepared for a major radiologic
ncident associated with the detonation of nuclear weapon or
mprovised nuclear device, the meltdown of a nuclear reactor,therapy 1 6 ( 2 0 1 1 ) 138–146 145
or the dispersal of radioactive contamination, such as by a
radiologic dispersal device.
Further studies of cancer risk with analyses of gene-
radiation interactions, are also of particular importance to
understand the radiation mechanisms and improve radiation
protection practice both in the case of further accidents and
for the protection of patients with medical exposures.
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